NCT05319431 - A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 28, 2022

Primary Completion Date

August 15, 2023

Study Completion Date

June 30, 2025

Conditions

Unresectable, Non-metastatic Hepatocellular Carcinoma

Interventions

BIOLOGICAL

AK104

Subjects will receive AK104 until disease progression or for a maximum of 24 months

DRUG

Lenvatinib

Subjects will receive lenvatinib until disease progression or for a maximum of 24 months

PROCEDURE

TACE

On demand TACE

Trial Locations (5)

The First Hospital of Beijing University, Beijing

Shandong Cancer Hospital, Jinan

Hunan Cancer Hospital, Changsha

Henan Cancer Hospital, Zhengzhou

Nanfang Hospital, Southern Medical University, Guangzhou